I last reviewed Intact Financial (IFC.to) in this July 30, 2025 post at which time the Q2 and YTD2025 results (as of June 30, 2025) were the most current. In that post, I disclose the purchase of 100 shares @ $292.36 in one 'Core' account and another 100 shares @ $292.85 in another 'Core' account [...]
In January 2025, on the advice of our tax accountants, we effected partial RRSP withdrawals as part of our RRSP meltdown strategy. I discuss the rationale for this strategy in prior posts. Based on the year-to-date performance of our investments, our tax accountants have instructed us to make further RRSP withdrawals. I like to acquire [...]
In several previous posts, including my April 3, 2025 Blackstone and Brookfield Exposure Increase post, I touch upon why it is wise to 'follow the money' if we want to create wealth. Invest In The Best In A Saturated Industry The asset management industry is saturated with many industry participants likely to: be absorbed by [...]
In my June 27, 2025 Accenture (ACN) post, I disclose my decision to initiate a position through a 'Core' account in the FFJ Portfolio. The company's share price has experienced weakness following this initial purchase. My long-term outlook for the company, however, remains positive. I have, therefore, been adding to my exposure and disclose increases [...]
When I last reviewed Cintas (CTAS) in this July 18, 2025 post, the company had recently released its FY2025 results and FY2026 guidance. Based on the currently available information and a $224.50 share price, I determined shares were too richly valued to warrant adding to my current exposure. Fast forward to September 4, 2025 and [...]
When I last reviewed S&P Global (SPGI) in my August 1, 2025 Wide Moat S&P Global’s Valuation Is Fair post, shares were trading at ~$546.50. The share price subsequently touched ~$579 on August 14. I did not expect to revisit SPGI until after its Investor Day on November 13, 2025. The company's share price, however, [...]
I last reviewed Copart (CPRT) in this May 28, 2025 post at which time the most current financial information was for Q3 and YTD2025. I, however, disclosed in my June 18 Copart’s Valuation Improves post, an additional increase in my CPRT exposure. With the release of Q4 and FY2025 results following the September 4 market [...]
Periodically, great companies temporarily fall out of favor with investors thus providing an investment opportunity. Intuitive Surgical (ISRG) is such a company. When I wrote my January 25, 2025 Beware Of Intuitive Surgical’s Valuation post, the share price had recently touched $616 before tracing back to $584. Despite the company's attractive long-term outlook, I viewed [...]
I last reviewed Agilent (A) in this May 30, 2025 post, at which time the most current financial information was for Q2 and YTD2025. With the release of Q3 and YTD2025 results and revised FY2025 outlook on August 27, I revisit this existing holding. Business Overview A has the following 3 reportable business segments: life [...]
When I last reviewed Veeva Systems (VEEV) in this May 29, 2025 post, I concluded that the company's valuation was no longer a bargain. At the time of that post, the most recent financial results were for Q1 2026. With the release of Q2 and YTD2026 results following the August 27 market close, let's revisit [...]